biosimilars

These replications, because they cannot be exact copies, are called "biosimilars."

Gary Puckrein: The Democratization of Health Care: Clinical Research and Quality Health Care for Minority Populations Gary Puckrein 2012

Drugmakers, investors and others are eager to gain more insight for the approval process for cheaper versions of biotech drugs, known as "biosimilars" -- a potentially multibillion-dollar market.

Reuters: Press Release 2011

Because of their complexity, generic copies of biotech drugs -- first introduced in the 1980s -- are known as "biosimilars."

Reuters: Press Release 2012

The 2010 health care law established a way for such biologic drugs, which can cost tens of thousands of dollars a year, to face competition from near generic versions, which are often called biosimilars.

NYT > Home Page By ANDREW POLLACK 2011

The 2010 health care law established a way for such biologic drugs, which can cost tens of thousands of dollars a year, to face competition from near generic versions, which are often called biosimilars.

NYT > Home Page By ANDREW POLLACK 2011

Drugmakers, investors and others are eager to gain more insight for the approval process for cheaper versions of biotech drugs, known as "biosimilars" -- a potentially multibillion-dollar market.

unknown title 2011

But zero in on the emerging markets' healthcare growth trend a bit more and you'll find that a large chunk of the expansion will come from the onset of "biosimilars" - i.e. generic copies of biotech drugs…

The Emerging Market Healthcare Trend That Nobody Is Talking About - Seeking Alpha 2011

Without data exclusivity, producers of generic biologics-commonly called "biosimilars" - could quickly siphon away innovator profits.

IPI PolicyBytes 2008

Without data exclusivity, producers of generic biologics-commonly called "biosimilars" - could quickly siphon away innovator profits.

IPI PolicyBytes 2008

Hopes that the U.S. and European market for these copies, known as biosimilars, will thrive are based on the fact that biological drugs with more than $60 billion in annual sales will lose patent protection by 2015, according to research firm Datamonitor.

Generics Companies Weigh In on Biological Drugs Goran Mijuk 2011

It created a pathway for federal approval of biosimilars, which are near-copies of biologic drugs, made from living cells.

If the Supreme Court Ends Obamacare, Here’s What It Would Mean By 2021